Hartmut Goldschmidt

85PUBLICATIONS
428CO-AUTHORS
Gene and molecular therapyMedical mycologyMedical bacteriologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (85)

|Jul 06, 2026
Author Correction: Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial.

|Jun 25, 2026
Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial.

|May 21, 2026
Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial.

|May 05, 2026
Infections in patients receiving daratumumab for newly diagnosed multiple myeloma: a pooled analysis of MAIA and ALCYONE.

|Feb 27, 2026
Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma: dynamics of MRD negativity in the IMROZ study.

Robert Z Orlowski, Meletios A Dimopoulos, Xavier Leleu

|Feb 24, 2026
Fiber intake associates with increased treatment response in patients with multiple myeloma along with changes in gut microbiome.

Lilli Sophie Sester, Iuliia Galeeva, Juliana de Castilhos

Pageof 15

Frequent Collaborators

27 joint publications

Elias Mai

21 joint publications

Marc S Raab

18 joint publications

Katja Weisel

18 joint publications

Carsten Müller-Tidow